Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC
Executive Summary
Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting
You may also be interested in...
Novartis And Daiichi Sankyo Obtain Japanese Price Listings, May Set Precedent For Combination Re-pricing
Japan's Central Social Medical Insurance Agency, also called Chuikyo, recently approved price listings for Novartis' and Daiichi Sankyo's respective potential blockbuster combination diabetes drugs, and the council also agreed to review drug pricing policy to encourage investment in drug innovation
Failed Post-MI Trial Foils Novartis' Higher ASPIRE-ations For Tekturna
ACC panelist: Study was not powered for outcomes, but doubling in death rates is still "very disturbing."
Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD
Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.